Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

26 Aug 2025

Abstract excerpt

Advanced prostate cancers respond to hormone therapy but outcomes vary and no predictive tests exist for informed treatment selection. To identify novel biomarker-treatment pairings, we examined associations between biological pathways and 14-year survival outcomes of patients randomized in practice-changing phase 3 trials (testing docetaxel or abiraterone). We included transcriptome-wide expression signatures...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer, Lipids, and Metabolism
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40865526
DOI: 10.1016/j.cell.2025.07.042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersPMID 40865526Read ↗

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trialSemantic proximity Read ↗

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancerSemantic proximity Read ↗

Genomic correlates of clinical outcome in advanced prostate cancerSemantic proximity Read ↗

AI-Powered cellular morphometric biomarkers discovered in needle biopsy of prostatic cancer predict neoadjuvant androgen deprivation therapy response and prognosis: an international multicenter retrospective studySemantic proximity Read ↗

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Semantic proximity Read ↗

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learningSemantic proximity Read ↗

Advancing Precision Medicine for Prostate Cancer Through GenomicsSemantic proximity Read ↗

Transcriptomics Signature from Next-Generation Sequencing Data Reveals New Transcriptomic Biomarkers Related to Prostate CancerSemantic proximity Read ↗

Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer.Semantic proximity Read ↗

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Semantic proximity Read ↗

MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancerSemantic proximity Read ↗

Prostate cancer heterogeneity: Discovering novel molecular targets for therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.